Clinical and regulatory failure
The RaniPill platform must prove safety, bioavailability, and efficacy across programs.
- Scope
- RaniPill GO and RaniPill HC
- Materiality
- high
Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. is a U.S.-based clinical-stage biotherapeutics company developing oral delivery technology for biologics and other drugs. Its core platform, the RaniPill capsule, is designed to deliver drug substances such as antibodies, proteins, peptides, and oligonucleotides through the gastrointestinal tract, with development activities centered in the United States and intended for global use.
−2 290,9 %
−1 817,1 %
+58,9 %
4.21
4.21
| % | |
|---|---|
| RaniPill GO | 20% Microtablet-based oral capsule designed to deliver small biologic doses with high bioavailability. |
| RaniPill HC | 20% High-capacity capsule under development for liquid payload delivery of larger biologics. |
| Partnered development and evaluation services | 60% Technology evaluation, transfer, and collaboration work performed for third-party biopharma partners. |
Rani’s customers are primarily biopharmaceutical companies that want to convert injectable biologics into oral...
- Biopharmaceutical collaboration partnersprimary
Companies that license or co-develop the RaniPill platform for specific biologic or drug programs.
- Technology evaluation customerssecondary
Partners that pay for evaluation services to assess whether their compounds can be delivered orally.
- Future commercial pharma customersemerging
Drug developers that may adopt the platform for approved products if clinical and regulatory milestones are met.
Rani is headquartered in the United States and conducts its development, engineering, and manufacturing activities...
- •Headquartered and primarily operated in the United States
- •Development and manufacturing capabilities are built in-house in the U.S.
- •Future commercialization is planned for the U.S., Europe, and Asia
- •Partner-led expansion could broaden market reach without a large sales force
- •Regulatory approvals will determine which countries can use the platform
Rani’s strategy is to advance the RaniPill platform through clinical development while partnering with biopharma...
01
Advance clinical validation of the RaniPill platformshort-term
Human data is needed to prove oral delivery performance and support regulatory progress.
02
Secure and expand biopharma collaborationsshort-term
Partner programs can create non-dilutive funding and validate the platform with named drug developers.
03
Scale manufacturing and device productionmedium-term
Commercial adoption will require reliable capsule manufacturing and supply chain control.
Rani faces the typical risks of a clinical-stage biotechnology company: uncertain clinical outcomes, regulatory...
Lack of commercial product revenue
The company is still in development, so revenue depends on future approvals and partner execution.
- Scope
- Platform-wide
- Materiality
- high
Partner concentration and collaboration dependence
A major portion of future economics may depend on one or a few collaboration agreements.
- Scope
- Chugai collaboration
- Materiality
- high
Financing and dilution risk
Development and manufacturing require capital before product sales are available.
- Scope
- Corporate funding
- Materiality
- high
Supply chain and manufacturing execution
The platform relies on third-party APIs/components and complex device manufacturing.
- Scope
- Single-source suppliers, automated lines
- Materiality
- medium
Nasdaq listing compliance
Failure to maintain listing standards could reduce liquidity and investor access.
- Scope
- Public equity market access
- Materiality
- medium
Contract revenue recognition
Small but important for collaboration economics
R&D expense classification
Primary driver of period expenses
Capitalization of manufacturing assets
Affects balance sheet size and near-term earnings
Non-controlling interest accounting
Impacts earnings attribution
Silence Therapeutics plc
SLN · Pharmaceutical Preparations
Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
PALISADE BIO, INC.
PALI · Biological Products, (No Diagnostic Substances)
ORAMED PHARMACEUTICALS INC.
ORMP · Pharmaceutical Preparations
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
: 29/04/2026